Introduction
============

Breast cancer is the most common neoplasia of women being diagnosed in approximately 211,000 women annually in the United States. In spite of earlier detection and improved treatment, it remains the second leading cause of cancer-related death in the United States and in other developed countries \[[@B1]\]. The genetic background of patients and the tumor\'s genetic and epigenetic anomalies create, in combination, molecularly distinct subtypes arising from distinct cell types within the ductal epithelium \[[@B2],[@B3]\]. This genetic complexity underlies the clinical heterogeneity of breast cancer limiting a rational selection of treatment tailored to individual patient/tumor characteristics.

Standard therapeutic decision-making (*i.e.*., NIH; St. Gallen consensus) rely on several clinicopathological factors such as patients\' age, tumor stage, grade, size, nodal status as well as hormone, and growth receptor status. The analysis of single molecular markers such as ki-67 and ERBB2 can also contribute to the therapeutic decision making. Although all of these factors have been correlated to patients\' survival in general, the same prognostic profile often results in dissimilar clinical outcomes in individual patients. Thus, conventional prognostic factors provide insufficient information to evaluate the heterogeneity of this disease and to make treatment more effective for individual patients.

One problem faced by present cancer therapy is the over-treatment of patients with chemotherapy, which is associated with severe toxicity and increasing healthcare spending without clear survival benefit over untreated controls \[[@B4],[@B5]\]. Because of the lack of adequate predictive markers (*i.e.*, ER, HER2/neu), nearly all patients receive routinely standard treatment in spite of grim changes of deriving any benefit. Therefore, the identification of molecular markers predictive of patients\' responsiveness to treatment is becoming a central focus of translational research.

Micro array technology offers insights about the simultaneous expression of thousands of genes providing global information about the transcriptional program associated with specific cellular or tissue conditions. This provides a high-throughput screening tool for the identification of molecular patterns of cancerous cell possibly associated with their sensitivity to therapy \[[@B6]-[@B9]\]. This strategy yielded significant contributions by dissecting beyond histopathologic features the molecular aspects of breast cancers, their association with lymph-nodal spread, metastatization and overall survival.

An important and so far seldom explored utilization of micro array technology is the identification of signatures predictive of responsiveness to chemotherapy. To get clear correlation between chemotherapeutic success and pre treatment gene expression we needed to rely in a model where chemotherapy is given before surgical resection so that its outcome could be evaluated. Beside the most common postoperative (adjuvant) chemotherapy, preoperative systemic therapy (PST) has been recently proposed for early-stage breast cancer. PST, uses cytotoxic drugs as the first modality of treatment allowing *in vivo*monitoring of the therapeutic responsiveness of a primary tumor over a given time period (*e.g*., 4 months). PST is offered preoperatively to patients with either large inoperable breast cancers or to patients interested in breast conserving surgery \[[@B10]-[@B16]\]. PST in general does not offer a survival advantage over standard adjuvant treatment but does identify those patients (up to 20%) with tumors reacting with a complete remission to the drug \[[@B17],[@B18]\]. Complete tumor remission, as confirmed by pathological examination, is often associated with prolonged disease free survival \[[@B19]-[@B22]\]. Additionally, PST can reduce the growth rate of residual distant micrometastases compared with classical adjuvant therapy \[[@B17]\].

By predicting which subset of tumors may respond to PST transcriptional profiling of pre-treatment samples could represent a powerful tool for patient selection.

Patients, Materials and methods
===============================

Patients
--------

This study was performed in collaboration with the Institute of Chemical Oncology, University of Düsseldorf, Germany, and Bayer Healthcare AG, Diagnostic Research, Leverkusen, Germany. All patients were recruited at the Interdisciplinary Breast Center IBC, City Hospital Düsseldorf. Patients signed an informed consent before any procedure. Study eligibility criteria required that participants presented with not previously treated primary breast cancer to be treated preoperatively.

Samples of primary breast carcinomas were collected between May 1999 and March 2003 from patients subjected to PST treatment with epirubicine/cyclophosphamide (EC). Since in several cases treatment modifications occurred or full pathological confirmation of response status was not conclusive not all samples were studied. Quality of samples related to delays in processing also limited the number of samples studied. In the end, a total of 56 tumor samples were identified from comparable treatment groups and were studied for marker discovery together with five normal breast samples excised from patient with benign pathology. Additionally, tumor samples removed from 27 patients treated with EC-based PST between December 2002 and September 2003 were analyzed as a second independent validation cohort. EC consisted of epirubicin 90 mg m^2^per day 1 in a short i.v. infusion, and cyclophosphamide 600 mg m^2^per day 1 in a short i.v. infusion. Four cycles of EC were administrated 14 days apart. Some patients received additionally Tamoxifen, Femara or seldom Zoladex for 4--5 weeks after EC course and before surgery. All tumor samples were collected as needle biopsies of primary tumors prior to any treatment. The biopsies were obtained under local anesthesia using Bard^®^MAGNUM™ Biopsy Instrument (C. R. Bard, Inc., Covington, U. S.) with Bard^®^Magnum biopsy needles (BIP GmbH, Tuerkenfeld, Germany) following ultrasound guidance. Samples were collected following routine conditions for pathological diagnosis following institutional review board guidelines. Pathological examination was carried out for all tumor samples by the same pathologist at the Interdisciplinary Breast Center IBC. The remainders of the samples were flash-frozen. After PST, all patients underwent a radical mastectomy or a lumpectomy and axillary node dissection at the discretion of the treating breast surgeon. Postoperative chemotherapy was administrated at the discretion of the treating medical oncologist. Breast or chest wall irradiation was administrated in selected patients. In addition, all women with ER-positive tumors were started on tamoxifen therapy. A detailed list of all samples and clinical data is presented in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} (see also Additional files [1](#S1){ref-type="supplementary-material"} and [2](#S2){ref-type="supplementary-material"}). Additionally, five normal breast samples from reduction mammoplasties were analyzed.

###### 

Clinical and molecular data on breast cancer patients (training set).

  Case       Response   Tumor reduction,%   Histology pre                                                   Age   ER   PR   BCL2   P53   KI67,%   CerbB2     Grading
  ---------- ---------- ------------------- --------------------------------------------------------------- ----- ---- ---- ------ ----- -------- ---------- ---------
  BC1492     NC         0                   invasive lobular                                                50    0    0    0      1     28       0          2
  BC1426     NC         0                   invasive ductal + intraductal(40%)                              62    1    1    400    0     2        1+ to 2+   1 a. 2
  BC1257     NC         0                   invasive lobular                                                69    1    1    180    0     16       1+ to 2+   2
  BC1176     NC         0                   invasive lobular a. tubular-lobular                             47    1    1    130    0     7        0          2
  BC1092     NC         0                   invasive lobular a. ductal                                      66    1    1    0      0     10       0          2
  BC1050     NC         0                   invasive tubular-lobular; multifocal                            60    1    1    60     0     3        0          2
  BC1034     NC         0                   intraductal a. invasive                                         43    1    1    0      0     2        0          2
  BC1044     NC         0                   invasive tubular-lobular                                        68    1    1    70     0     6        0          1
  BC1466     pCR        100                 invasive ductal a. intraductal(30%)                             57    0    0    0      0     26       3+         2
  BC1255     pCR        100                 invasive lobular                                                57    1    0    60     1     26       0          2
  BC1254     pCR        100                 medullary                                                       62    0    0    0      0     70       1+         3
  BC1180     pCR        100                 invasive lobular a. ductal                                      32    0    0    0      0     20       1+         2
  BC1159     pCR        100                 invasive lobular a. ductal                                      40    0    0    70     0     70       1+ to 2+   2
  BC1042     pCR        100                 non-typical medullary a. intraductal (bifocal)                  38    0    0    10     0     35       0          3
  BC1032     pCR        100                 invasive lobular a. ductal                                      58    0    0    0      0     15       3+         2
  BC1443     PR/CR      94                  invasive lobular a. ductal                                      61    1    0    10     0     30       3+         2
  BC1167     PR         0                   invasive lobular                                                71    1    1    400    0     8        0          2
  BC1162     PR         0                   invasive lobular                                                66    1    1    70     0     7        1+         2
  BC1143     PR         0                   invasive ductal a. intraductal(5%)                              54    1    1    210    0     17       1+         2
  BC1138     PR         0                   invasive lobular; multifocal                                    57    1    1    80     0     13       1+         2
  BC1100     PR         0                   invasive tubular-lobular                                        55    1    1    140    0     4        0          1
  BC1040     PR         0                   invasive ductal                                                 40    1    1    294    0     28       0          2
  BC1170     PR         0                   invasive lobular a. ductal bifocal                              67    1    0    210    0     4        2+ to 3+   2
  BC1140     PR         10                  left: invasive lobular                                          73    1    1    180    0     14       0          2
  BC1418     PR         12                  left:bifocal invasive tubular-lobular                           57    1    0    300    0     7        2+         1
  BC1420     PR         15                  invasive ductal a. lobular; multifocal                          63    1    1    400    0     3        2+         2
  BC1491     PR         18                  invasive lobular                                                64    1    1    300    0     7        0          2
  BC1515     PR         20                  invasive ductal                                                 64    1    1    300    1     10       0          2
  BC1445     PR         20                  right:invasive lobular; bifocal                                 64    1    0    160    0     15       1+ to 2+   2
  BC1036     PR         24                  invasive ductal                                                 58    1    1    392    0     15       0          2
  BC1308     PR         25                  invasive lobular; multifocal                                    74    0    0    0      0     16       2+         2
  BC1133     PR         25                  invasive ductal                                                 53    0    0    294    0     50       0          3
  BC1259     PR         32                  invasive ductal a. lobular (Herd1) a. invasive ductal (Herd2)   59    1    0    300    0     16       2+ to 3+   2
  BC1498     PR         33                  invasive ductal; bifocal                                        62    1    0    15     0     19       3+         3
  BJ_40613   PR         35                  invasive ductal                                                 61    1    1    100    0     4        2+         2
  BC1166     PR         35                  invasive ductal a. lobular                                      45    1    1    140    0     14       1+ to 2+   2
  BC1142     PR         35                  invasive lobular; bifocal                                       53    1    1    20     0     18       1+         2
  BC1422     PR         40                  invasive ductal a. lobular; multifocal                          53    1    1    360    0     2        2+         2
  BC1132     PR         40                  invasive ductal                                                 41    1    1    30     1     18       2+         3
  BC1096     PR         40                  invasive ductal                                                 46    1    1    294    0     13       0          2
  BC1129     PR         42                  invasive tubular-lobular                                        52    0    0    0      0     15       2+         2
  BC1130     PR         45                  invasive lobular                                                42    1    1    140    0     NA       0          2
  BC1131     PR         45                  invasive ductal (pulmonal, ossar)                               63    1    0    300    0     45       0          2
  BC1256     PR         50                  invasive lobular                                                60    0    0    0      1     17       1+         2
  BC1446     PR         50                  invasive lobular; bifocal                                       53    1    1    140    0     35       1+         2
  BC1116     PR         53                  invasive lobular                                                49    1    1    180    0     3        0          2
  BC1415     PR         55                  invasive lobular; multifocal                                    53    0    0    15     1     40       0          2
  BC1141     PR         55                  invasive lobular                                                52    1    1    500    0     20       0          2
  BC1495     PR         60                  invasive tubular a. intraductal (10%); bifocal                  58    1    0    300    0     2        0          2
  BC1497     PR         75                  invasive lobular                                                42    1    1    300    0     5        2+         2
  BC1160     PR         75                  invasive lobular                                                47    0    1    30     0     35       0          2
  BC1038     PR         75                  invasive ductal                                                 35    1    1    294    0     30       0          2
  BC1095     PR         85                  invasive tubular-lobular                                        60    1    0    294    0     1        0          1
  BC1024     PR         88                  invasive lobular                                                59    1    1    70     0     18       0          2
  BC1101     PR         75--85              invasive lobular; multifocal                                    75    1    0    180    0     10       3+         2
  BC1139     PR         89--90              invasive lobular with DCIS parts; multifocal                    55    1    1    NA     0     15       NA         1

ER and PgR status were determined by immunohistochemistry. 1 -- positive (\>7 fmol/mg protein); 0 -- negative (\<7 fmol/mg protein). HER2/neu status: copies of HER2/neu gene. Status of p53 oncogene: 0 - \<180 score; 1 - \>180 score. NA -- not available.

###### 

Clinical and molecular data on breast cancer patients (test set).

  Case        Response   Tumor reduction, %   Histology pre                                 Age   ER   PR   BCL2   P53   KI67, %   CerbB2     Grading
  ----------- ---------- -------------------- --------------------------------------------- ----- ---- ---- ------ ----- --------- ---------- ---------
  BC1843      NC         0                    invasive ductal; bifocal                      63    1    1    200    0     18        1+         2
  BC1850      NC         0                    invasive lobular                              58    1    1    300    0     6         0          2
  BC1862      NC         0                    invasive lobular a. intraductal               59    1    1    196    0     11        1+         2
  BC1871      NC         10                   invasive lobular                              46    1    1    140    1     24        0          2
  BC1869      pCR        100                  invasive ductal                               60    0    0    0      0     50        0          3
  BC1864      pCR        100                  invasive a. intraductal (DCIS; 80%)           55    0    0    0      0     50        0          2
  BC1421      pCR        100                  invasive lobular                              71    0    0    0      1     26        0          2
  BC1870      cCR        100                  invasive ductal                               43    0    0    0      1     35        1+ to 2+   2
  BC1861^1^   PR         40                   invasive ductal a. intraductal (very small)   36    0    0    0      0     35        0          3
  BC1879      PR         47                   invasive ductal                               37    1    1    500    0     45        0          2
  BC1866      PR         40                   invasive lobular                              52    1    1    300    1     24        2+ to 3+   2
  BC1837      PR         90                   invasive ductal                               69    0    0    0      0     48        1+         3
  BC1838      PR         80                   invasive lobular                              59    1    0    50     0     20        1+ to 2+   2
  BC1842      PR         92                   invasive ductal                               68    0    0    0      0     29        1+         2
  BC1834      PR         0                    invasive ductal a. intraductal (very small)   60    1    1    30     0     10        3+         3
  BC1858      PR         0                    invasive lobular                              62    1    1    140    0     16        1+         2
  BC1880      PR         40                   invasive ductal and intraductal (5%)          62    1    1    200    0     26        0          2
  BC1881      PR         62                   invasive ductal                               72    0    0    0      1     22        0          2
  BC1849      PR         22                   invasive ductal                               52    1    0    200    0     19        3+         2
  BC1839      PR         10                   invasive ductal                               62    0    0    45     1     16        0          2
  BC1513      PR         33                   invasive lobular; multicentr.                 60    1    1    300    0     10        0          2
  BC1877      PR/NC      50                   left: invasive lobular a. CLIS Type-A         53    1    1    300    0     6         1+         2
  BC1853      PR/NC      0                    invasive lobular                              51    1    1    400    0     14        0          2
  BC1448      PR         68                   medullary invasive                            50    1    1    30     1     38        3+         3
  BC1134      PR/NC      5                    invasive lobular                              73    1    0    70     0     14        0          2
  BC1840^2^   PR         25                   invasive ductal                               45    1    1    60     0     35        2+ to 3+   3
  BC1848      PR         85                   invasive ductal; bifocal                      42    1    0    500    1     28        3+         2

Note: 1 -- This patient has received 4 × EC and, additionally, 4 × Taxol; 2 -- this patient has received 3 × EC and, additionally, 3 × FEC.

Immunohistochemistry (IHC)
--------------------------

Hematoxilin/eosin-stained sections from tumor specimens were examined to assess the relative amounts of tumor cells, benign epithelium, stroma, and lymphocytes. Standard clinical parameters, such as estrogen receptor-α (ER), progesterone receptor (PgR), proliferation marker (ki-67), tumor suppressor p53, regulator of apoptosis Bcl2, protooncogene cerbB2/HER2neu, epidermal growth factor receptor (EGFR) were assessed according to routine bio- and/or immunohistochemical methods.

Immunohistochemical staining was performed on 5-μm paraffin sections. Sections were deparaffinized in xylene and re-hydrated. Epitope retrieval was performed by heat induction in Target Retrival Solution pH6.1 (DAKO, DakoCytomation GmbH, Hamburg, Germany). Tissues were blocked for endogenous peroxidase in a 0.3% H~2~O~2~solution for 15 min. Monoclonal antibodies (ERa: ER1D5 DAKO 1:35, PR: PGR636 DAKO 1:50, bcl-2: Clone 124 1:200 DAKO, EGFR: 31G7 CYTOMED 1:20, cerb2/Her-2/neu polyclonal DAKO 1:250, and ki67 (MIB-1) DAKO 1:200) were used for specific epitope detection. The ChemMate DAKO peroxidase/DAB Detection Kit was used for linking and staining. Slides were counterstained with methyl green and coverslipped with entelan. Histologic scores were calculated by multiplying color intensity (range 0 to 5) with proportion of cells staining positive.

Response Criteria
-----------------

Response to the treatment followed the Unio Internationale Contra Cancrum criteria \[[@B23]\]. pCR (pathological diagnosis based complete responders), was defined as absence of invasive carcinoma in the breast by the examining pathologist and lack of lymph nodal involvement. cCR (clinical complete responders) was defined as clinical absence of invasive carcinoma of the breast. This parameter was used as a surrogate for pCR in one occasion when a patient declined post-PST surgical excision. PR (partial responders) was determined as a reduction in the tumor mass of both perpendicular dimensions ranging from 10% to 75% of the initially measured tumor size based on dynamic contrast-enhanced magnetic resonance imaging or magnetic resonance tomography (MRT), and sometimes on both, MRT and ultrasonography. NC (non-responders or [n]{.ul}o [c]{.ul}hange) was defined as an absence of tumor reduction or an increase in tumor size (stable or progressive disease). The percent of tumor reduction (Table [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}) was calculated as a ratio between pathologic tumor size \[cm\] after neoadjuvant chemotherapy at the time of surgical excision compared to the size of tumors defined clinically at the time of diagnosis. More details are available as Additional files [3](#S3){ref-type="supplementary-material"} and [4](#S4){ref-type="supplementary-material"} from the JTM Web page.

RNA Preparation and Microarray Analysis
---------------------------------------

Total RNA was extracted from cell lysates of ground tissue and subsequent purification with RNeasy mini spin columns (Qiagen, Hilden, Germany). Subsequent washing and elution steps were performed according to manufacturer\'s instructions. High-quality RNA was obtained as suggested by well-preserved 28S and 18S ribosomal RNA bands (present in an approximately 2:1 intensity ratio), along with A260/A280 ratios between 1.8 and 2.0. Quality and integrity of total RNA was tested with a Bioanalyzer 2100 (Agilent Technologies Inc., Palo Alto, CA, USA). Gene expression analysis was performed on an Affymetrix Human Genome U133A GeneChip platform containing 22,283 probes. Preparation and processing of labeled and fragmented cRNA targets, hybridization and scanning procedures were carried according to the manufacturer\'s protocol (Affymetrix, Santa Clara, CA, USA) \[[@B24]\]. Starting material for labeling consisted of 5 μg of total RNA from each tumor specimen. Labeling was limited to one cycle of *in vitro*transcription. Thus, starting with 5 μg of total RNA, approximately 50 to 60 μg of amplified RNA (cRNA) could be generated, which could be used in multiple microarray experiments. The cRNA was quantified by Agilent Nano Chip technology and evaluated for size relative to pure polyadenylated RNA. Fifteen micrograms of cRNA were subsequently used for hybridization. After washing and staining arrays were scanned by Gene Array scanner 2500 (Affymetrix). Hybridization intensity data were automatically acquired and processed by Affymetrix Microarray Suite 5.0 software. The expression level (average difference) of each gene was determined by calculating the average of differences in intensity (perfect match-mismatch) between its probe pairs as described elsewhere \[[@B25]\]. Scans were rejected if the scaling factor exceeded 2 or \"chip surface scan\" revealed scratches, specks or gradients affecting overall data quality (Refiner, GeneData AG, Basle, Switzerland).

Quantitative Real-Time PCR.
---------------------------

Aliquots of total RNA used for GeneChip expression analysis were used for quantitative RT-PCR with an ABI PRISM 7900 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). cDNA for PCR amplification was generated by oligo dT primed reverse transcription (Superscript First Strand System, Invitrogen Corporation, Carlsbad, CA, USA) including DNAse I treatment. Primers and probes were designed with the Primer Express software (Applied Biosystems, Foster City, CA, USA) and spanned the same gene region of the respective Affymetrix probe set. Labeled oligonucleotides were obtained from Eurogentec s.a. (Liege, Belgium). Absolute copy numbers were normalized according to *GAPDH*as a reference gene. The primer/probes were prepared by mixing 25 μl of 100 μM stock solution \"upper primer\", 25 μl of 100 μM stock solution \"lower primer\" plus 12,5 μl of the 100 μM stock solution TaqMan-probe (FAM/TAMRA) and adjusted to 500 μl with H~2~O (Primer/probe-mix). PCR reactions using cDNA generated from 1.5 ng total RNA were performed in duplicates in a volume of 10 μl. This included TaqMan universal Mix (Eurogentec s.a.) according to manufacturer\'s protocol in a 384-well format and 1 μl of the P&P mix. Thermal cycler parameters were 2 min at 50°C, 10 min at 95°C and 40 cycles, each consisting of a 15 s denaturation step at 95°C and a 1 min annealing/extension step at 60°C. Relative abundance of a gene transcript was calculated either by the ΔΔCt method or by arbitrarily defined RNA copy number estimates at a Ct = 24 as 10^6^copies. Subsequent analysis included normalization steps such as median centering and per gene median division.

Data Filtering
--------------

Fifty-six primary breast cancer and 5 non cancerous breast tissue samples were analyzed as a training set for marker discovery. Raw data was acquired using Microsuite 5.0 software from Affymetrix and normalized following the standard practice of scaling the average of all gene signal intensities to a common arbitrary value (TGT = 100). Gene expression data were stored including *P*-value, as generated by Microsuite 5.0 software, for quality assessment of individual measurements for each transcript. The data-file was imported into Expressionist Analyst software package (GeneData AG) for further statistical analysis. To enhance quality we excluded gene probe sets for the following reasons. Fifty-nine probe sets corresponding to hybridization reference (housekeeping genes, *etc.*) as identified by Affymetrix were removed with the exception of *GAPDH*and β *-actin*, for which a 3\' biased probe set was included. One hundred genes, whose expression levels are routinely used for normalization of the HG-U133A and HG-U133B GeneChip versions \[[@B26]\], were also removed from the analysis. These genes reflect a very homogenous expression pattern among several human tissues and could therefor be categorized as \"house keeping\" genes. Genes with potentially high levels of noise (81 probe sets) frequently observed with low absolute expression values (below 30 relative signal units (RSU) in all experiments) were also removed. The remaining genes were preprocessed to eliminate those (3,196) whose signal intensities were not significantly different (*P*\> 0.04) from their background levels and thus labeled as \"Absent\" by MicroSuite 5.0. To apply a higher stringency to the data, we eliminated genes whose significance levels (*P*\< 0.04) were only reached in 10% of the breast cancer samples (3,841 probe sets). Data for the remaining 15,006 probe sets were used for the subsequent analysis.

Statistical Analysis
--------------------

For the analysis we applied a similar strategy to the one applied by Wang E. and colleagues \[[@B27]\] to predict immune responsiveness of melanoma metastases. Genes differentially expressed by lesions characterized by different responsiveness to PST were identified with the nonparametric Wilcoxon rank sum test, two-sample independent Students\'t-test and Welch test. Probes were ranked in order of significance (SUM-Rank test) combining the results of these tests using as a cut-off *P-*value \< 0.05 and fold change between groups \>2. The Kruskal-Wallis and ANOVA tests were applied when two distinct groups (i.e. pCR *vs*NC) with extreme response patterns where studied in the presence of a third intermediate group (PR). All statistical tests were two-tailed. Principal components analysis (PCA) and hierarchical clustering were applied for data display and structural analysis and in certain steps for dimensional (probe set) reduction. All these different tools were used as implemented in the GeneData Expressionist Analyst software package and were only modified by selection of starting parameters and appropriate distance weight matrices. Additionally, partial least squares discriminant analysis for multivariate data (PLS-DA) with SIMCA-P software (Umetrics, AB, Umea, Sweden) was used.

Results
=======

Preliminary analysis about ER status and inflammation
-----------------------------------------------------

Previous studies \[[@B28]-[@B31]\] reported that patients with negative estrogen receptor (ER) status respond better to PST compared to those with a positive one. In addition, *PgR1*gene expression may affect outcome. Furthermore, patients with ER-negative tumors suffer shorter disease-free and overall survival \[[@B32]-[@B34]\]. ER status is also associated with a characteristic gene expression profile independent of other clinical/pathological parameters \[[@B35],[@B36]\]. Therefore, we separately studied genes known to be associated with ER signaling. We analyzed previously the expression profile of breast cancer in two patient cohorts with positive and negative ER status (not part of this study). The complete gene list and expression data within the two cohorts is available ([Additional file 5](#S5){ref-type="supplementary-material"}). We identified 828 Affymetrix probe sets by ANOVA and *t*-test (*P*\< 0.005) with a median fold change of 1.2 or above. Analysis of the 828 ER-related signatures in the 56 tumors from the present study correlated well with ER-α status by immunohistochemistry. To avoid the influence on clinical outcome of ER-specific signatures and identify alternative, ER-independent predictors of response and survival, these genes were excluded

We also excluded genes related to immune function since we could not predict the effect that the heterogeneity of immune infiltrates might bear on the transcriptional profile of individual lesions. Immune genes (1,025) were identified and excluded. The complete list of excluded genes is available ([Additional file 6](#S6){ref-type="supplementary-material"}). Many of the excluded genes are members of immunoglobulin families. The final data set contained 13,145 probe sets. Although there is currently plenty of interest about the impact of immunity as a predictor of clinical outcome, this was beyond the purpose of this work and will be considered in a subsequent manuscript.

Determination of predictor genes
--------------------------------

Starting with the training cohort, we built response subclasses based on the post surgical clinicopathological examination. Eight of the 56 training cases experienced a pCR and eight progressed (NC). To identify the most predictive genes for each class we implemented a comparison schedule for the training set as follows:

\(I\) PR vs. NC (n = 40 vs. 8); (II) pCR vs. PR (n = 8 vs. 40), and (III) pCR vs. NC (n = 8 vs. 8). These comparisons were carried out by non-parametric *t-*test, Welch, Wilcoxon, Kolmogorov-Smirnov tests using the Expressionist Analyst software (GeneData AG). Differentially expressed genes were considered those reaching a significance cut off *P-value*of \< 0.05 in all tests; 2,301 were identified. Additional restrictions were then applied (at least 2-fold change of median expression level and average expression more than 30 RSU (relative signal units) in all three groups) resulting in only 1,512 probe sets useful for further analyses.

For the \"three-group tests\" (pCR vs. PR vs. NC) statistical significance was measured with the Kruskal-Wallis and one-way ANOVA tests with a cut off *P-*value of \< 0.05 identifying 414 probe sets. Overlap of the gene lists (1,512 probe sets and 414 probe sets) by Venn diagram analysis qualified 397 probe sets. This high stringency potentially eliminated genes of interest but decreased the false discovery rates of random selected genes at *P*-value cut off \<0.05. PCA using all predefined tissue classes: non cancerous breast tissue pCR, cCR, PR and NC was applied to the 397 probe sets. Separation of pCR and cCR tumors on the one side and NC samples on the other was defined by 2 most distinguishing components. We applied a cutoff on the correlation matrix of the PCA and filtered genes at \< -0.4 and \> 0.4. This sorted out 325 by eliminating 72 probe sets.

We then excluded from the remaining 325 genes those known to be specifically expressed in blood vessels, adipocytes, and muscle tissues based on differential expression profiling of tumor cells and normal cells after their separation by laser capture microdissecction or by comparing breast tumor\'s gene expression profiles with expression profiles of normal blood vessels, adipose and muscle tissue samples reducing the number of genes by 61. The list of the excluded 61 genes is available ([Additional file 7](#S7){ref-type="supplementary-material"}). Rank ordering of the remaining 264 genes\' significance was determined by SUM-Rank test for all samples and compared to the original 13,145 genes.

In addition, two classifier genes were identified (*FHL1*and *CLDN5*) highly discriminative between most \"normal\" tissue samples and all breast cancer samples analyzed. Whereas these genes are expressed at very high levels in normal breast tissue their low level expression was rarely detected in malignant breast samples. We combined these 2 genes with 57 most discriminative genes from 264 filtered probe sets ([Additional file 8](#S8){ref-type="supplementary-material"}). Such combination allows simple and fast separation of normal tissue samples from malignant ones, which might be useful for routine clinical diagnostics. A detailed table containing raw data for 59 genes and 83 tumors is available as supplemental information (Additional files [9](#S9){ref-type="supplementary-material"} and [10](#S10){ref-type="supplementary-material"}).

Validation on independent cases
-------------------------------

The determined classifiers could be subdivided into three categories: those genes/probe sets capable to distinguish between (a) normal breast and breast cancer tissues (2 genes, *FHL1*and *CLDN5*), (b) pCR or cCR from unfavorable outcomes (PR or NC) (31 probe sets or \"favorable response signature\"), and (c) NC and PR (26 probe sets or \"poor response signature\"). We expected that both signatures, favorable and poor, would separate the two most extreme classes pCR and NC and effectively recognize the respective expression patterns. These classifiers were challenged against samples from an independent test cohort (n = 27; 4 pCR, 4 NC, 19 PR; see Table [2](#T2){ref-type="table"} or [Additional file 2](#S2){ref-type="supplementary-material"}). Classification was performed by *k*-NN (*k*= 3) following a three step decision tree based on the 59 genes listed above. All 27 tumor samples were correctly qualified as cancerous tissues using the two-gene signature (*FHL1*and *CLDN5*). Whit the \"favorable response signature\" a group of 8 tumor samples was classified as CR or PR. Finally, the rest of the tumors were classified as NC or PR by the \"poor response signature\". There were four potentially wrong classified cases. Results of classification for the test cohort are shown in Table [3](#T3){ref-type="table"}. Summarized results of validation, as well as sensitivity, specificity positive and negative predictive values (PPV and NPV, respectively) for each class are shown in Table [4](#T4){ref-type="table"}.

###### 

Comparison of predicted and pathologic response in test set.

  Case     Tumor reduction,%   Response, pathologic   Predicted response PCA cross validated by *k*-NN   Predicted response PLS-DA model 1   Predicted response PLS-DA model 2
  -------- ------------------- ---------------------- -------------------------------------------------- ----------------------------------- -----------------------------------
  BC1843   0                   NC                     NC                                                 NC                                  PR
  BC1850   0                   NC                     NC                                                 NC                                  NC
  BC1862   0                   NC                     NC                                                 NC                                  PR
  BC1871   10                  NC                     NC                                                 NC                                  PR
  BC1869   100                 pCR                    CR                                                 CR                                  CR
  BC1864   100                 pCR                    CR                                                 CR                                  CR
  BC1421   100                 pCR                    CR                                                 CR                                  CR
  BC1870   100                 cCR                    CR                                                 CR                                  CR
  BC1861   40                  PR                     PR                                                 CR                                  CR
  BC1879   47                  PR                     PR                                                 NC                                  NC
  BC1866   40                  PR                     PR                                                 CR                                  CR
  BC1837   90                  PR                     CR                                                 CR                                  CR
  BC1838   80                  PR                     PR                                                 NC                                  NC
  BC1842   92                  PR                     PR                                                 PR                                  PR
  BC1834   0                   PR                     PR                                                 PR                                  CR
  BC1858   0                   PR                     NC                                                 NC                                  NC
  BC1880   40                  PR                     PR                                                 PR                                  PR
  BC1881   62                  PR                     NC                                                 PR                                  PR
  BC1849   22                  PR                     NC                                                 NC                                  PR
  BC1839   10                  PR                     NC                                                 NC                                  PR
  BC1513   33                  PR                     PR                                                 NC                                  PR
  BC1877   50                  PR                     PR                                                 NC                                  NC
  BC1853   0                   NC                     NC                                                 NC                                  NC
  BC1448   68                  PR                     CR                                                 CR                                  CR
  BC1134   5                   NC                     NC                                                 NC                                  NC
  BC1840   25                  PR                     NC                                                 NC                                  NC
  BC1848   85                  PR                     CR                                                 CR                                  CR

Note: complete pathologic response shown as CR when predicted.

###### 

Summarized results of validation on the test cohort.

                   Predicted response k-NN   Predicted response PLS-DA; model 1   Predicted response PLS-DA; model 2
  ---------------- ------------------------- ------------------------------------ ------------------------------------
  predicted CR     7                         9                                    10
  other            20                        18                                   17
                                                                                  
  predicted PR     9                         4                                    9
  other            18                        23                                   18
                                                                                  
  predicted NC     11                        14                                   8
  other            16                        13                                   19
                                                                                  
  Sensitivity CR   100                       100                                  100
  Specificity CR   87                        78                                   74
  PPV              57                        44                                   40
  NPV              100                       100                                  100
                                                                                  
  Sensitivity PR   53                        24                                   35
  Specificity PR   100                       100                                  100
  PPV              100                       100                                  67
  NPV              56                        43                                   39
                                                                                  
  Sensitivity NC   100                       100                                  50
  Specificity NC   76                        62                                   76
  PPV              55                        43                                   38
  NPV              100                       100                                  84

PCA and Hierarchical Clustering
-------------------------------

A PCA plot was created displaying the position of each tumor sample from training and test cohorts (83 tumors) using three main Eigenvectors (Fig. [1A](#F1){ref-type="fig"}). The PCA was performed with the set of 57 response predictive genes for illustration purpose. The two most disparate response groups (pCR and NC) are clearly separated with the exception of one NC case, BC1492, which clusters with pCR tumors. This plot is consistent with *k*-NN cross-validation results for training cohort, which defined that NC case BC1492 as complete response. Hierarchical clustering of all 83 tumors and 57 response predicting genes is shown in Fig. [1B](#F1){ref-type="fig"} and [1C](#F1){ref-type="fig"}: eleven of twelve pCR tumors are organized in one sub-branch of the sample dendrogram and NC tumors are placed into the separate dendrogram branch.

![Clustering of gene expression data for 57 genes from 83 breast tumors corresponding training and test cohorts. A. PCA analysis of response groups and gene expression. The visualization of high-dimensional data in three-dimensional principal components. Individual samples from training and test cohorts are labeled according to three response groups: *green*and *light green*-- pCR; *yellow*and *light yellow*-- PR; *red*and *light red*-- NC. The distance between samples reflects their approximate degree of correlation. B. Hierarchical clustering presents the clustered samples in columns and the clustered 57 genes in rows. A color representation of gene expression levels is shown with the scale on the *left*side. The 57 genes used fir both clustering methods were obtained by multi-step statistical approach, as described in \'A predictor gene set determination\' section of Results. C. An enlarged version of sample dendrogram, which reflects similarities in their expression profiles.](1479-5876-3-32-1){#F1}

Partial least squares discriminant analysis (PLS-DA)
----------------------------------------------------

Direct linear discriminant analysis was applied to compare the previous results and test the potential of our first classifier model. PLS-DA applies well to the large number of predictors and the multicollineality. Supervised PLS-DA analysis uses independent (expression levels) and dependent variables (classes) for class comparison applying multivariate statistical methods such as soft independent modeling of class analogy (SIMCA) and partial least squares modeling with latent variables to allow simultaneous analysis of all variables \[[@B37]-[@B42]\]. Additionally, PLS-DA provides a quantitative estimation of the discriminatory power of each descriptor by means of *VIP*(variable importance for the projection) parameters. *VIP*values represent an appropriate quantitative statistical parameter ranking descriptors (gene expression values) according to their ability to discriminate different classes.

PLS-DA was carried out on the original 13,145 probe sets that passed the QC filtering process in the training cohort. Although this process may lead to an over parameterized model with poor prediction properties, it provides a preliminary assessment of the most important discriminative variables. Two independent models were tested each consisting of two classes: model 1 (class 1 -- pCR, class 2 -- NC, and PR cases were excluded); model 2 (class 1 -- pCR, class 2 -- NC and PR together). The model with three classes (pCR, NC and PR) demonstrated rather poor prediction power being strongly dependent on the definition of partial response (Table [1](#T1){ref-type="table"}). Possibly the comparison of pathological estimates (post treatment) compared to clinical measurements (pre-treatment) over estimated the tumor reduction measurements and biased the attribution of samples as PR rather than NC.

Those variables satisfying the criteria of expression levels above 60 RSU (as a mean value in at least one of each sample group, pCR and NC), ratio (pCR/NC) \>1.9 or \<0.55, and *VIP*of \>1.9 were retained. Figure [2](#F2){ref-type="fig"} shows a scatter plot of samples from the training set grouped according to the two components for either PLS in model 1 (96 probe sets; Fig. [2](#F2){ref-type="fig"}) or in the model 2 (90 probe sets; Fig. [3](#F3){ref-type="fig"}) after the second iteration. The numbers next to the symbols are the sample IDs as detailed in Table [1](#T1){ref-type="table"}. It is apparent that pCR and NC samples are clearly discriminated. However, the results of permutation tests for both models (data not shown) demonstrated that both reduced models were still over-parameterized. Thus, we retained the 20 probe sets deduced from model 1 and 20 probe sets from model 2 with highest *VIP*values. In both cases, models performed much better than expected by chance.

![PLS discrimination according to tumor response class using the variables selected by PLS (*VIP*\> 1.9) and ratio (pCR/NC) \> 1.9 or \< 0.55. Model 1 (PR cases were deleted; class 1 -- pCR, *black dots*; class 2 -- NC, *black squares*); 96 probe sets (cDNAs) retained.](1479-5876-3-32-2){#F2}

![PLS discrimination according to tumor response class using the variables selected by PLS (*VIP*\> 1.9) and ratio (pCR/NC) \> 1.9 or \< 0.55. Model 2 (class 1 -- pCR, *black dots*; class 2 -- NC, *black squares*and PR, *gray triangles*); 90 probe sets retained.](1479-5876-3-32-3){#F3}

Two groups of selected probe sets were compared and nine probe sets were found to be represented in both lists, which were deduced from model 1 and 2. A combined list containing 31 probe sets was used for model validation (Table [5](#T5){ref-type="table"}) by applying PLS-DA to the second, independent group of tumors (n = 27; Table [2](#T2){ref-type="table"}) to test the discriminative power of the final gene list. The results are presented in Table [3](#T3){ref-type="table"}. PLS-DA classified partially responding tumors with good (\> 60% tumor shrinkage) or very poor response to therapy as complete response (*e.g*., BC1837, BC1848, BC1448) or no response (*e.g.*, BC1877, BC1134, BC1840) respectively. This observation indicates that for further studies the monitoring of tumor shrinkage during PST is pivotal to correctly judge the final response classification and it might have been the major limitation of this study. Both statistical approaches, one that yielded the 59 gene and PLS-DA were compared and identified 19 genes in common. PLS-DA alone demonstrated a lower predictive power compared to the first multi-step analysis combined with *k*-NN classification.

###### 

Top 31 genes extracted from two different models from PLS-DA SIMCA.

  Gene Symbol   Gene Description                                                                                         Ref. Sequences   Unigene ID
  ------------- -------------------------------------------------------------------------------------------------------- ---------------- ------------
  KPNA2         nuclear localization sequence receptor hSRP1alpha, karyopherin alpha 2 (RAG cohort 1 importin alpha 1)   NM_002266        4504896
  *HDAC2*       transcriptional regulator homolog RPD3 histone deacetylase 2 similar to yeast RPD3                       NM_001527        4557640
  *PRKAB1*      5-AMP-activated protein kinase beta-1, non-catalytic subunit                                             NM_006253        18602783
  *IMPDH2*      inosine monophosphate dehydrogenase (IMPDH2)                                                             NM_000884        4504688
  *YR-29*       hypothetical protein clone YR-29                                                                         NM_014886        7662676
  *CD2BP2*      CD2 antigen (cytoplasmic tail)-binding protein 2                                                         NM_006110        5174408
  FHL2          heart protein (FHL-2) four and a half LIM domains 2                                                      NM_001450        4503722
  *DDB2*        damage-specific DNA binding protein p48 subunit (DDB2; 48 kD)                                            NM_000107        4557514
  *ASNS*        asparagine synthetase                                                                                    NM_001673        4502258
  XPA           XPAC protein xeroderma pigmentosum complementation group A                                               NM_000380        4507936
  *PLA2G7*      LDL-phospholipase A2 phospholipase A2 group VII (platelet-activating factor acetylhydrolase plasma)      NM_005084        4826883
  *BTBD2*       BTB (POZ) domain containing 2 hypothetical protein FLJ20386 EST                                          NM_017797        8923361
  *CCNG1*       cyclin G1 clone MGC:6                                                                                    NM_004060        \-
  *PDHB*        pyruvate dehydrogenase E1-beta subunit d pyruvate dehydrogenase (lipoamide) beta                         NM_000925        4505686
  *MKI67*       mki67a (long type)antigen of monoclonal antibody Ki-67                                                   NM_002417        4505188
  *TNRC15*      KIAA0642 protein trinucleotide repeat containing 15                                                      AL_045800        18550089
  *RPL17*       ribosomal protein L17                                                                                    NM_000985        14591906
  *GNG12*       DKFZp586B0918 (from clone DKFZp586B0918)                                                                 NM_018841        \-
  *RPL17*       ribosomal protein L17                                                                                    NM_000985        14591906
  *DKC1*        Cbf5p homolog (CBF5) dyskeratosis congenita 1 dyskerin nucleolar protein                                 NM_001363        15011921
  DCTN4         dynactin p62 subunit dynactin 4 (p62)                                                                    NM_016221        14733974
  *FLJ20273*    RNA-binding protein                                                                                      NM_019027        9506670
  *FLJ11323*    hypothetical protein EST                                                                                 NM_018390        8922994
  *MGC11242*    hypothetical protein MGC11242 ESTs                                                                       NM_024320        13236560
  *SRR*         serine racemase Homo sapiens cDNA                                                                        NM_021947        8922495
  *ARL3*        48c8 ADP-ribosylation factor-like 3 EST                                                                  NM_004311        4757773
  CCNB2         cyclin B2                                                                                                NM_004701        10938017
  *MAD2L1*      MAD2 protein MAD2 (mitotic arrest deficient yeast homolog)-like 1                                        NM_002358        6466452
  *LIG1*        membrane glycoprotein LIG-1d                                                                             NM_015541        18554950
  *PMSCL1*      polymyositisscleroderma autoantigen 1 (75 kD) EST                                                        NM_005033        4826921
  APBB2         amyloid beta (A4) precursor protein-binding, family B                                                    NM_173075        18557629

Note: -- Genes in common with EC predictor (Table 3).

Confirmation of expression measurements by real-time RT-PCR
-----------------------------------------------------------

Real-time RT-PCR (qPCR) measurement of gene expression levels on the same RNAs used for GeneChip hybridization experiments obtained from 32 breast tumors from training and test cohorts was performed on 46 genes selected from those presented in Table [3](#T3){ref-type="table"}. Primer and probes were designed in regions within or close to the target region of the GeneChip oligonucleotides. A Ct value of 24 was empirically considered to represent 10^6^RNA copies per well based on spiking experiments. Raw data from real-time RT-PCR are presented in Supplemental Data on the Web page, as above, along with Affymetrix GeneChip\'s data. Relative expression as measured by the GeneChip was compared with qPCR results adjusting the median expression of all 46 genes within one sample to 100 relative units. To detect the relative difference in expression between samples for each gene, all measurements were divided by the median expression of this gene. This median normalization was carried out for both platforms independently. Raw and normalized data for Affymetrix and TaqMan platforms are shown in [Additional file 11](#S11){ref-type="supplementary-material"}. In order to compare the individual measurements and the relative abundance of each transcript we preformed hierarchical clustering with the data generated with the GeneChip system. We performed this clustering (Fig. [4](#F4){ref-type="fig"}) with a correlation matrix on the samples as well as on the genes while the distance measurement was carried out with an average weight matrix. Once having the cluster of the GeneChip data in place we ordered all samples and all genes for the qPCR data in the same order as derived from the previous clustering. This operation resulted in very similar heat-maps as depicted in Figure [4](#F4){ref-type="fig"} with an overall correlation of *R*^2^= 0.73. We also performed independent clustering of the qPCR data (Fig. [5](#F5){ref-type="fig"}), which resulted in similar correlation trees.

![Confirmation of expression measurements by real-time RT-PCR. GeneChip median expression for 46 genes from Table 3 within one sample was adjusted to 100 RLU. Then, all measurements were median centered for each gene. Hierarchical clustering algorithm was applied to median normalized expression data of 46 genes from 39 tumor samples from training and test cohorts. Hierarchical clustering presents the clustered samples in columns and the clustered 46 genes in rows. A color representation of gene expression levels is shown with the scale on the *left*side (pCR represented in *green*, NC represented in *red*). Clustering of the data was performed according a correlation analysis with an average distance determination. The threshold Ct values obtained in real-time RT-PCR were converted into an arbitrary RNA-copy number Ct value of 24, which was then empirically settled to 10^6^RNA copies per well. These measurements were median centered, as for microarray data. All data for samples and genes were ordered according to the hierarchical structure of the microarray data set in Fig. 3A for Affymetrix platform.](1479-5876-3-32-4){#F4}

![Confirmation of expression measurements by real-time RT-PCR Independent clustering of the qPCR data for both, Affymetrix and TaqMan platforms resulted in similar correlation trees.](1479-5876-3-32-5){#F5}

Discussion
==========

The aim of this study was to identify a multigene predictor of response to EC in a PST. Several recent studies demonstrated that gene expression profiling can predict response in the neoadjuvant setting \[[@B43]-[@B47]\]. Since the patient-specificity of such predictors remain questionable \[[@B48]\], further attempts devoted to the understanding of the process (es) underlying responsiveness to systemic therapy are of obvious importance.

Primary systemic chemotherapy is often being used to downstage large and locally advanced breast tumors in patients prior to surgery. There is increasing evidence that response and, particularly, complete response to neoadjuvant chemotherapy predicts improved disease-free and overall survival \[[@B49]-[@B51]\]. Unquestionable, pathological complete response (pCR) is not a synonym for cure, since a risk remains for metastatic disease. But such risk is decreased in association with the down-staging of the primary tumor and the achievement of a node negative status confirmed at the time of surgery. Therefore, it is reasonable to suggest that a good response to neoadjuvant therapy may correspond to survival benefit.

The role of biological characteristics and/or molecular markers as predictor of sensitivity to specific treatments has been extensively studied \[[@B52]-[@B56]\]. However, their role in response prediction remains unclear. Results from different studies are often contradictory and, consequently, no individual biological marker can be reliably used clinically for prediction of response to chemotherapy \[[@B57],[@B58]\].

The patients analyzed in this study were part of a much larger cohort (n = 319) receiving treatment with EC-based PST. We have observed in this patient population that age, histologic grade, estrogen receptor (ER), progesterone receptor (PgR), levels of oncogene B-cell leukemia 2 (Bcl2), proliferation-related Ki-67 antigen (ki-67), and epidermal growth factor receptor (EGFR) expression were related to response in a univariate analysis, also confirmed by Colleoni *et al*. \[[@B33]\] in preoperative settings. However, in a multivariate model it was only ki-67 expression that predicted a better pathological response (*P*= 0.011), and this factor was linked to the patient\'s age \[[@B59]\]. Thus, a true predictive marker that could be measured by routine methods (*e.g*., IHC) to identify patients likely to benefit from neo-adjuvant EC remains elusive.

Several studies on breast cancer assessed classifiers predictive of survival \[[@B60]-[@B65]\]. A Dutch group reported 70 genes predictive of disease recurrence in women with lymph-node-negative primary breast cancer and confirmed the findings in a second study comprising additional 198 patients \[[@B65]\]. This study could assign some women to a low-risk category beyond the discriminating power of conventional histopathological criteria.

However, the concordance among different studies on survival of breast cancer patients is low. Data inconsistency can be particularly explained by the use of different microarray technologies and different patients\' demographics. In addition, subtleties in data analysis may explain some discrepancies since there is no standardize method for expression data analysis when a large number of data points per individual are studied in relatively low sample populations.

In this study, we accurately discriminated samples that had a high tumor content from normal breast tissue based on the previous demonstration that *FHL1*and *CLDN5*can serve as such predictors. Then, we identified predictors in cancer tissues from primary tumors by identifying genes capable of segregating two distinct classes of tumors according to response to treatment (pCR *vs*NC). \"Favorable outcome signature\" could predict complete remission of a primary tumor with \>90% sensitivity. Some genes found to be highly expressed in pCR samples belong to the \"biological topic\" of mitosis and cell proliferation (*e.g*. *MAD2L1*, *CCNB2*). This is concordant with the observations we \[[@B59]\] and others made on the *ki-67*expression and the negative ER status in responding tumors \[[@B66]\]. Possibly, actively dividing tumors, either driven by the lack of hormonal control or by other signals such as via the insulin receptor pathway may respond best. The \"poor outcome signature\" distinguishing tumors unlikely to respond to PST included *DDB2*or *XPA*, involved in DNA damage repair which makes perfect logical sense. The highest predictive value was sought in a stepwise manner by comparing pCR to NC cases and comparing predictors of each group by multi-step statistical approaches and *k*-NN (*k*= 3) validation. This classifier could predict with a remarkable level of accuracy a pathological response in the subsequent cohort of 27 patients used for validation. It is also possible that there were mis-assignments of responding cases especially in borderline cases that responded with minor changes in size or bifocal tumors. Ultra-sound imaging applied for size determination prior to chemotherapy might not be comparable to the accurate measurements that pathologists can make on resected samples. Thus, 10 cases in the training set considered as PR might not have qualified if comparable measurements could be used before and after therapy. This undefined error might have partially affect our statistical analysis decreasing the sensitivity of the model adopted (*i.e.*, predict many NC cases as PR and *vice versa*).

We also observed that application of different statistical algorithms to the data analysis lead to the extraction of overlapping predictor signatures (19 of 57 genes were in common). Although some of the genes identified by the PLS-DA could have been dismissed by the stringent filtering criteria applied, both analytical approaches could predict pCR. Accuracy of NC prediction could only be achieve through the stepwise identified signatures. Further in depth interpretation of the biological processes associated with the genes identified statistically will probably enhance the robustness of our findings in the future \[[@B67]-[@B69]\] \[70\].

We attempted to override the risk of overfitting of the model based on the training data (*i.e*., finding a mass of less relevant genes that may lead to the loss of a few relevant ones). The prediction accuracy was relatively high but was limited by the number of validation events (pCR or NC) so far analyzed suggesting that improved selection predictor genes among the ones identified based on a larger validation study may increase the accuracy of our findings and as a consequence their clinical value. We are currently collecting samples for a second validation cohort receiving EC based PST under similar conditions at an independent institution.
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